COVID-19 Response

The Oxford BioDynamics facility remains operational and is continuing to provide biomarker support for clinical trials worldwide during this challenging period.

EpiSwitch™ selected for prognostic and predictive profiling of COVID-19 patients. 

Read more…

Innovation Saving Lives

We are a biotechnology company with a proprietary epigenetic biomarker discovery platform, EpiSwitch™, based on the latest advances in regulatory genome architecture and its link to clinical outcomes and patient stratification.

EpiSwitch™ biomarkers based on chromosomal conformation signatures are a critical cog in personalised medicine.

Technology to select the right drug at the right dose at the right time for the right patient.

Our Publications on EpiSwitch™

White blood cells from Prostate cancer patients carry distinct Chromosome Conformations.

Pchejetski, D., et. al.
J of Urology

Chromosome conformation signatures response to methotrexate in early rheumatoid arthritis.

Carini et. al.
J Transl Med

A chromosomal conformation signature for a priori prediction of ALS progression subtypes.

Salter, et. al.,
F1000 Research

Glycaemic progression study among population in Penang, Malaysia.

Patel, JS, et. al.,
Diabetes Asia 2017 Conference

A Prospective Study of Two Distinct Epigenetic Signatures for ALS Diagnosis and Prognosis.

Westra, W, et. al.,
16th Annual Northeast Amyotrophic Lateral Sclerosis Meeting

Epigenetic signatures and early detection of neurodegenerative diseases: Development of stratifying biomarker for ALS in Asian cohorts.

Lim, CR, et. al.,
World Congress of Neurology

PerkinElmer releases application note outlining the importance of EpiSwitch™ technology in determining epigenetic biomarkers using the LabChip GX Touch Platform.

OBD and PerkinElmer
Application Note; 25 August 2017

Super-Enhancers and Broad H3K4me3 Domains Form Complex Gene Regulatory Circuits Involving Chromatin Interactions.

Cao, F, et. al.,
Scientific Reports

Chromatin Conformation Signatures Associated with Epigenetic Deregulation of the FIP1L1 and PDGFRA Genes.

Grand, FH, et. al.,
American Society of Haematology

Epigenetic footprints for neurodegenerative and autoimmune conditions: a comparative analysis.

Hunter, E, et. al.,
The Lancet Neurology Conference